U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000075: Polycystic Liver Disease Questionnaire (PLD-Q)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000075: Polycystic Liver Disease Questionnaire (PLD-Q)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Hepatology and Nutrition (DHN)

DDT COA Number
DDT COA #000075

Instrument Name
Polycystic Liver Disease Questionnaire (PLD-Q)

Disease/Condition
Polycystic Liver Disease (PLD)

Concept of Interest
PLD symptoms

Context of Use
Adult patients with Gigot stage II or III PLD

COA Type
PRO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
Marie Hogan
Jeff Sloan

Contact(s)
Marie Hogan

Date Accepted into CDER’s COA Qualification Program
February 8, 2016

Submission and Regulatory Correspondence History

Qualification Submission

Date

FDA Submission Decision & Recommendations

Date

--

--

Transition Letter to 507 Process

9/5/19

Back to Top